Background and aim: Capecitabine is an orally bioavailable prodrug that is converted to 5-fluorouracil through several enzymatic steps, the last of which is mediated by thymidine phosphorylase (TP). TP has been reported to be expressed at higher levels in cancer tissue compared with normal counterpart.
introduction
Breast cancer (BC) represents the most frequent malignancy in women and the second cause of cancer-related deaths [1] . The worldwide incidence exceeds a million of new cases each year and the mortality is 400 000 per year [2] .
It is estimated that 30%-40% of BC patients will eventually develop metastases. On average, the survival from the diagnosis of metastatic disease is approximately of 2 years. Sites of metastasis and disease phenotypes are major determinants of prognosis [3, 4] .
There are several therapeutic options for metastatic BC: endocrine treatment, chemotherapy, radiotherapy, biologic treatment, alone or in combination. The choice is mostly on the basis of patient's (age, comorbidities, social status, and personal preference) and disease's (receptor status, HER-2 status, site of metastasis, disease-free interval, and symptoms) characteristics, but previous treatments have to be taken into account before proposing a new therapeutic option. In particular, mechanism of action, cross-resistance, and cumulative dose of previously used agents may influence the therapeutic choice.
According to the National Comprehensive Cancer Network (NCCN) guidelines, for patients with a hormonal receptorpositive and low-burden disease (only bone metastasis or asymptomatic visceral metastasis) a hormonal treatment is preferable. Otherwise, in hormonal nonresponsive tumors or in symptomatic patients with aggressive disease, chemotherapy would be the treatment of choice.
In metastatic setting, chemotherapy could be administered as single agent or in combination. The NCCN guidelines for BC in this setting recommend anthracyclines, paclitaxel, docetaxel, capecitabine, vinorelbine (with level of evidence 2A), and gemcitabine (with level of evidence 2B) [5] .
The response rate (RR) to first-line therapy with anthracycline, taxane, capecitabine, vinorelbine, and gemcitabine varies from 25% to 60% with a time to progression (TTP) of 6 months. The RR halves when these drugs are used in second or third line, although a great variability among different studies is reported [4] .
capecitabine
Capecitabine is the first oral fluoropyrimidine approved by the Food and Drug Administration for metastatic BC after the use of an anthracycline and taxane regimen or in presence of contraindication to anthracycline therapy [6] .
Capecitabine is metabolized to 5-fluorouracil (5-FU) through a three-step process (Figure 1 ): the first consists of the capecitabine conversion in 5#-deoxy-5-fluorocytidine by carboxylesterase in the liver and the second by its conversion to 5#-DFUR (5#-deoxy-5-fluorouridine) by the cytidine deaminase present in normal and tumor tissues. Finally, 5#-DFUR is metabolized to the active form 5-FU by thymidine phosphorylase (TP). TP represents the rate-limiting enzyme in the activation of 5#-DFUR and capecitabine, suggesting that sensitivity of tumor cells to these prodrugs might be enhanced by increasing TP expression [7] . thymidine phosphorylase TP is an enzyme responsible for nucleoside metabolism and it has been involved in antiapoptotic activity and angiogenesis. Studies indicate that TP may also increase metastatic potential of cancer cells by inducing the expression of several matrix metalloproteinases. In addition, TP acts in the salvage cascade of DNA metabolism in response to various types of stresses [8] .
TP is a homodimer of 45-kDa subunits and was first described >50 years ago [9] . In the 1970s TP was purified from both Escherichia coli and Salmonella typhimurium. In the 1980s a molecule extracted from human platelets demonstrated to have the same effects of TP (platelet-derived endothelial cell growth factor), and it turned out to be the same molecule [8, 10] .
TP is detectable in healthy and tumor tissues, but TP expression in solid tumor appears to be 3-to 10-fold increased with respect to the healthy adjacent tissues [11] [12] [13] . TP expression is highly variable among different types of cancer. Kamoshida et al. [14] evaluated TP expression in 115 samples of primary resected tumors not treated with chemotherapy. They showed that TP is more frequently expressed in BC, followed by lung cancer (adenocarcinoma and squamous cell carcinoma), renal cancer, hepatocellular cancer, gall-bladder adenocarcinoma, and the intestinal type of gastric adenocarcinoma. On the contrary, there was low TP expression in colon cancer and diffuse-type gastric cancer.
The proangiogenic activity of TP could explain the more aggressive behavior of TP-expressing tumors since it confers a greater resistance to apoptosis. Of note, an association of TP and other proangiogenic molecule expression is common, such as vascular endothelial growth factor that acts as an angiogenic growth factor increasing the microvessel density and endothelial stimulation, thus having a cooperative role in neovascularization [10, 15] . Overexpression of TP was found to correlate significantly with an increase in neovascularization and poor prognosis [8] .
TP is up-regulated by stress such as hypoxia, radiation, and chemotherapeutic damage. Several types of cytokines such as interleukin 1, tumor necrosis factor-a, and interferon -c also up-regulate the expression of TP in both nonmalignant and malignant cells, this strengthening the hypothesis that TP expression is stress induced [8] . Among the chemotherapeutic agents that could up-regulate TP, there are anthracycline, taxanes, cyclophosphamide, and platinum compounds [10] .
TP expression has been prospectively evaluated in 55 BC patients considered operable before and after the administration of preoperative chemotherapy containing anthracyclines and/or taxanes [16] . A statistically significant increase of cytoplasmic TP expression on tumor tissue after the preoperative chemotherapy was detected.
Similarly, Toi et al. [8] analyzed TP expression before and after chemotherapy in 92 BC patients considered operable. The chemotherapy regimens used were heterogeneous, since they were anthracycline based but taxanes and 5-FU could be added [8] . The authors showed an increase in TP expression after the preoperative treatment, and this increase seemed to be more frequent in patients receiving anthracyclines and cyclophosphamide and taxanes. No change in TP expression was noted after 5-FU-containing chemotherapy. Toi et al. suggested two possible explanations for this phenomenon: one relies on the high concentration of 5-FU that might downregulate TP expression, since high concentrations of pyrimidine substrate change or down-regulate the expression of nucleoside metabolism enzymes. A second hypothesis is that 5-FU might selectively kill or suppress TP-overexpressing cells.
The prognostic significance of TP expression in solid tumors was first described in colorectal carcinoma. Takebayashi et al. [17] evaluated TP expression in tumor tissue samples of 163 colon cancer patients. Significant association was noticed between TP expression and the following variables: tumor size, extent of invasion, lymph node metastasis, and lymphatic and original article Annals of Oncology venous invasion. The authors concluded that high levels of TP expression in colorectal cancer are associated with more extensive angiogenesis, unfavorable clinical and laboratory findings, and poor clinical outcome. Subsequent studies confirmed the prognostic role of TP also in other types of cancer: transitional cell carcinoma of the bladder [18] , cervical cancer [19] , and gastric carcinoma [20] .
As far as BC is concerned, the prognostic role of TP is not clear, since contrasting results are reported in different studies. Li et al. [21] evaluated the association between TP-messenger RNA expression in tumor tissue and some prognostic factors (grade, tumor size, lymph node status, phase S cellular fraction, ploidy, and clinical variables) with no statistically significant correlation.
Yang et al. [22] analyzed TP expression in 182 BC patients with evidence of association between TP expression, low grade, and low p53 expression. TP-positive tumors seemed to have a longer TTP and overall survival (OS) with a limited effect on angiogenesis.
Tominaga et al. [23] published a retrospective study on TP expression in 650 samples of BC. The results showed that low TP expression represented a favorable prognostic factor.
Our group [24] recently suggested that TP may have a role in predicting the response to capecitabine. We carried out a correlative study on TP expression as part of a phase II trial in which 47 BC patients received weekly docetaxel in combination with capecitabine for metastatic disease. In this study, patients with high TP tumor expression, evaluated by immunohistochemistry (IHC), achieved a significantly longer TTP with capecitabine.
The present study aims at evaluating the relationship between TP tumor expression and therapeutic benefit from capecitabine in a population of advanced BC patients receiving capecitabine as single agent.
patients and methods
This is a retrospective analysis of 61 cases of metastatic BC patients who received at least three cycles of capecitabine as single agent in metastatic setting. All patients had been followed at the Oncology Department, University Hospital of Udine, Italy, from October 2002 to August 2007. IHC for estrogen receptor (ER) and progesterone receptor (PgR) status, HER-2/neu status (rabbit polyclonal, Hercept Test, Dako kit), and proliferating activity (MIB-1 expression; mouse monoclonal, Ki67; Dako, A/S Glostrup, Denmark) had been carried out on paraffin-embedded samples of the primary tumor or, if not available, of metastatic lesions, according to previously reported method [25] . In addition, all the specimens were processed for TP expression.
immunohistochemical analysis of TP IHC was carried out at a single central laboratory using a primary mouse anti-TP monoclonal antibody (clone p-P-GF.44G; Abcam, Cambridge, UK). TP was assessed on 5-lm sections of paraffin-embedded tissue samples. Endogenous peroxidase activity was inhibited by incubating the slides in 0.3% H 2 O 2 in absolute methanol for 5 min. Antigen retrieval was carried out in a water bath at 98°C (40 min in 1 mmol/l EDTA buffer, pH 8.0). The tissues were blocked with 20% goat serum for 20 min and then incubated overnight at 4°C with mouse monoclonal anti-TP antibody diluted 1 : 100 (Roche Diagnostics, Mannheim, Germany). For staining detection, the EnVision+ Detection System (Dako, A/S, Glostrup, Denmark) was used according to the manufacturer's recommendations. In each experiment, a negative control was included, in which the primary antibody was replaced by mouse ascites. Liver Kupffer cells served as a positive control.
evaluation of IHC
TP expression was evaluated on tumor cells (nuclear and cytoplasmic staining) and on stromal cells (cytoplasmic staining). Nuclear expression of TP was expressed as percentage of positive cells. Staining intensity as well as percentage of stained cells was considered in assessment of cytoplasmic staining according to the method described by Tsuda et al. [26] . The intensity of cytoplasmic and stromal immunoreactivity was scored as 0, 1, 2, or 3 denoting negative, weak, moderate, and strong staining, respectively. The percentages of areas of each category (0-3) of staining were estimated and, regardless of positive or negative staining, the category of the largest area of cancer or stromal tissue was reported as the representative score for each case. Therefore, for statistical analysis, the TP expression level for each case was putatively defined as positive if the predominant intensity was 2 or 3. 
assessment of treatment activity and efficacy
The RR was evaluated according to the Response Evaluation Criteria in Solid Tumors [27] : the evaluation was carried out at baseline and every 2-3 months of treatment with capecitabine.
TTP was defined as the time between the beginning of therapy with capecitabine and disease progression (uncensored) or last follow-up (censored).
statistical analysis
The Mann-Whitney and chi-square tests were used to study the association between the TP (nuclear and cytoplasmic) expression and the other variables (categorical and nominal).
Univariate analysis was carried out by comparing TTP and the following variables: performance status at the beginning of capecitabine treatment, stage at diagnosis, grade, ER and PgR status, HER-2 status, MIB-1, TP expression, presence of visceral metastasis at the beginning of capecitabine treatment, and treatments received before capecitabine.
A TTP analysis was carried out in subgroups defined by:
cytoplasmic TP expression (according to the literature and to our previous experience on association of TP expression and clinical benefit from capecitabine [24] , nuclear TP expression was not considered); previous therapy containing anthracyclines and taxanes; previous therapy containing taxanes; and previous therapy containing anthracyclines.
The variables that showed a statistically significant association (P < 0.05) with therapeutic benefit from capecitabine were subsequently studied through a multivariate analysis. The differences in terms of TTP between the variables of interest were analyzed with a log-rank test.
results
Patients and tumor characteristics are summarized in Table 1 . As regards TP expression in different compartments, no statistically significant association with age at diagnosis, hormonal receptor status, proliferation activity (MIB-1), and HER-2 status (Mann-Whitney and chi-square tests) was evident.
A statistically significant association was highlighted between nuclear and cytoplasmic expression of TP (Mann-Whitney, Annals of Oncology original article P < 0.0001) and between cytoplasmic expression of TP and grade (chi-square test, P = 0.018, G3 versus G1, G2; G3 was associated with absence of TP expression).
Considering the entire population, median TTP resulted of 6.5 months (range 1.4-33) and median OS was 13.7 months (range 2.5-56.53). Among all the variables considered, a statistically significant association between TTP and ER positivity was observed: TTP in patients with ER-positive tumor was significantly longer (median 6.9 months) than in patients with ER-negative tumor (median 2.8 months, P = 0.01). A trend of association, although not significant, was evident for stage at diagnosis, site of metastasis, and capecitabine position among the treatments received. In particular, patients with early-stage disease at diagnosis presented a median TTP of 6.8 versus 3.9 months for patients with advanced disease at diagnosis (P = 0.09). TTP was longer in patients with nonvisceral metastasis (median 7.2 months) than in patients with visceral metastasis at the beginning of capecitabine treatment (4.7 months, P = 0.08). Patients who received capecitabine as first or second line presented a median TTP of 3.3 months when compared with patients treated with capecitabine beyond second line (median 7.7 months, P = 0.06).
On the basis of our previous studies that showed induction of TP expression by anthracyclines and taxanes [16] and the relationship between TTP and TP expression [24] , we conducted a subgroup analysis considering treatments received before capecitabine. In the subgroup of patients with TPexpressing tumor, TTP was significantly longer in patients who received anthracyclines plus taxanes before capecitabine (median TTP 7.5 versus 3.3 months, P = 0.01, Figure 2) . The benefit of a previous anthracycline-and taxane-based therapy was lost in TP-negative tumor patients (P = 0.36, log-rank test).
Similarly, patients with a TP-positive tumor showed a longer TTP if they received taxanes before capecitabine than if they did not receive this treatment (7.3 versus 3.4 months, P = 0.03, Figure 3 ). Patients treated with anthracyclines before capecitabine did not show any difference in TTP irrespective of TP expression.
Results, expressed as hazard ratios, are summarized in Table 2 . Moreover, considering the best response to capecitabine, an association or a trend was noticed between:
anthracyclines and taxanes before capecitabine and clinical benefit (chi-square test, P = 0.02); anthracyclines before capecitabine and clinical benefit (P = 0.09); and taxanes before capecitabine and clinical benefit (chi-square test, P = 0.04).
These data are summarized in Tables 3-5 .
On multivariate analysis, the following variables resulted to be independent predictors of TTP: ER status, visceral lesions, and the line of treatment with capecitabine, as illustrated in Table 6 . PD, progression disease. Annals of Oncology original article
The relationship between cytoplasmic TP expression and therapeutic benefit from capecitabine is reported in Tables 7  and 8 .
discussion
In the present study, patients with TP-positive BC and previously treated with a taxane-based therapy (also in combination or in sequence with anthracyclines) achieved a better clinical benefit and a significantly longer TTP than patients who did not receive these treatments before capecitabine. These results strengthen the hypothesis that, when a cytoplasmic TP expression is present, previous therapy with TP-inducing chemotherapy could increase the efficacy of capecitabine treatment. Moreover, this observation leads to hypothesize that anthracyclines and taxanes impact on enzymatic TP induction process if a baseline TP expression is present. On the contrary, if TP is not expressed, these agents seem to have no impact in the TP induction process.
Having received previous treatment with taxanes in combination or not with anthracyclines renders the patients more likely to obtain a benefit from capecitabine (Tables 7 and 8) .
Several studies support the TP-inducing effect of anthracyclines and taxanes [8, 10, 16] , although the present study suggests that taxanes could have a greater role in the TPinducing process. In addition, in a previous work, we demonstrated that, after neo-adjuvant chemotherapy, an increase in TP cytoplasmic tumor expression was more common in response to taxane-containing regimens [44%, 95% confidence interval (CI) = 26%-63%] than in regimens without taxanes (25%, 95% CI = 5%-57%) [16] .
Furthermore, we recently reported the results of a phase II trial in which patients with metastatic BC received docetaxel 36 mg/m 2 on days 1, 8, and 15 and capecitabine 625 mg/m 2 b.i.d. from days 8 to 21 [24] . Notably, when outcomes were compared according to IHC-detected TP status, patients with TP-positive tumors experienced a more than doubled TTP (10.5 versus 4.2 months, log-rank test, P = 0.009). Taken together, the results of these studies indicate that IHC evaluation of TP expression deserves to be investigated as potential predictor of therapeutic benefit from capecitabine in patients treated with taxanes (concurrently or sequentially) for metastatic BC. However, these correlative studies must be viewed as hypothesis generating and interpreted with caution because of the small sample sizes.
Interestingly, recent evidence suggests that ER status could have potential role in predicting benefit from capecitabine. In particular, two studies presented in form of abstract at the 44th American Society of Clinical Oncology annual meeting reported a better outcome in patients with ER-positive tumors treated with capecitabine in the adjuvant and advanced setting, respectively [28, 29] . In conclusion, this work provides further evidence that TP expression in BC tissue could represent a marker of sensitivity to capecitabine treatment. More prospective studies, with translational approach, are desirable to confirm the predictive and prognostic role of TP. The biologic and clinic rationale of the TP-inducing agents in sequence and/or in combination to capecitabine could represent the basis for further studies leading to optimize the BC therapy either in metastatic or adjuvant/neo-adjuvant settings. 
